Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors
17 mars 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Participate in the Cowen 42nd Annual Health Care Conference
01 mars 2022 16h05 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
24 févr. 2022 16h01 HE
|
Oyster Point Pharma, Inc.
FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in...
Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express Scripts
22 févr. 2022 07h00 HE
|
Oyster Point Pharma, Inc.
One of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic and High-Performance Formularies,...
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
16 févr. 2022 16h05 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 janv. 2022 17h08 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022
21 déc. 2021 16h05 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index
15 déc. 2021 09h26 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference
30 nov. 2021 19h09 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease
24 nov. 2021 07h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...